News archive
Showing 687 results
February 2018
-
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3… -
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
- US label updated to include Cosentyx® (secukinumab) data in moderate to severe scalp psoriasis - one of the difficult-to-treat types of psoriasis(1,2)- Approximately half of all 125 million… -
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
January 2018
-
Media Release
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-- Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1)-- Data… -
Media Release
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media Release
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
- Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate… -
Media Release
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media Release
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
- Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal… -
Media Release
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer